FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317686095> ?p ?o ?g. }

• W4317686095 endingPage "e005007" @default.
• W4317686095 startingPage "e005007" @default.
• W4317686095 abstract "Background Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). Prior immunotherapy was permitted >28 days before study treatment. Patients received intravenous V937 on days 1, 3, and 5 (also on day 8 in part B) of the first 21-day cycle and on day 1 of subsequent cycles for eight cycles. Three ascending dose-escalation cohorts were studied. Dose-escalation proceeded if no dose-limiting toxicities (DLTs) occurred in cycle 1 of the previous cohort. In part B, patients also received pembrolizumab 200 mg every 3 weeks from day 8 for 2 years; dose-expansion occurred at the highest-dose cohort. Serial biopsies were performed. Results No DLTs occurred in parts A (n=18) or B (n=85). Grade 3–5 treatment-related adverse events (AEs) were not observed in part A and were experienced by 10 (12%) patients in part B. The most frequent treatment-related AEs (any grade) in part B were fatigue (36%), pruritus (18%), myalgia (14%), diarrhea (13%), pyrexia (13%), influenza-like illness (12%), and nausea (12%). At the highest tested dose, median intratumoral V937 concentrations were 117,631 copies/mL on day 8, cycle 1 in part A (n=6) and below the detection limit for most patients (86% (19/22)) on day 15, cycle 1 in part B. Objective response rates were 6% (part A), 9% in the NSCLC dose-expansion cohort (n=43), and 20% in the urothelial cancer dose-expansion cohort (n=35). Conclusions Intravenous V937+pembrolizumab had a manageable safety profile. Although V937 was detected in tumor tissue, in NSCLC and urothelial cancer, efficacy was not greater than that observed in previous studies with pembrolizumab monotherapy. Trial registration number NCT02043665 ." @default.
• W4317686095 created "2023-01-22" @default.
• W4317686095 creator A5005677013 @default.
• W4317686095 creator A5013942253 @default.
• W4317686095 creator A5015256213 @default.
• W4317686095 creator A5015428877 @default.
• W4317686095 creator A5016669132 @default.
• W4317686095 creator A5016686763 @default.
• W4317686095 creator A5029588412 @default.
• W4317686095 creator A5042503296 @default.
• W4317686095 creator A5046981381 @default.
• W4317686095 creator A5049524331 @default.
• W4317686095 creator A5050435057 @default.
• W4317686095 creator A5051789976 @default.
• W4317686095 creator A5055537555 @default.
• W4317686095 creator A5060495866 @default.
• W4317686095 creator A5061348179 @default.
• W4317686095 creator A5066673450 @default.
• W4317686095 creator A5067211956 @default.
• W4317686095 creator A5068910261 @default.
• W4317686095 creator A5072284989 @default.
• W4317686095 creator A5072499869 @default.
• W4317686095 creator A5088007604 @default.
• W4317686095 date "2023-01-01" @default.
• W4317686095 modified "2023-10-11" @default.
• W4317686095 title "Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors" @default.
• W4317686095 cites W1583371546 @default.
• W4317686095 cites W1982488143 @default.
• W4317686095 cites W2019607817 @default.
• W4317686095 cites W2028182670 @default.
• W4317686095 cites W2086591619 @default.
• W4317686095 cites W2100158834 @default.
• W4317686095 cites W2109274792 @default.
• W4317686095 cites W2152546348 @default.
• W4317686095 cites W2152897456 @default.
• W4317686095 cites W2166662937 @default.
• W4317686095 cites W2198093519 @default.
• W4317686095 cites W2314439797 @default.
• W4317686095 cites W2465221794 @default.
• W4317686095 cites W2560367415 @default.
• W4317686095 cites W2570159314 @default.
• W4317686095 cites W2572174216 @default.
• W4317686095 cites W2588916311 @default.
• W4317686095 cites W2740235105 @default.
• W4317686095 cites W2750781282 @default.
• W4317686095 cites W2925446385 @default.
• W4317686095 cites W2954843732 @default.
• W4317686095 cites W3092306917 @default.
• W4317686095 cites W3132892284 @default.
• W4317686095 cites W3182433262 @default.
• W4317686095 cites W4210394199 @default.
• W4317686095 cites W4226109861 @default.
• W4317686095 doi "https://doi.org/10.1136/jitc-2022-005007" @default.
• W4317686095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36669791" @default.
• W4317686095 hasPublicationYear "2023" @default.
• W4317686095 type Work @default.
• W4317686095 citedByCount "1" @default.
• W4317686095 countsByYear W43176860952023 @default.
• W4317686095 crossrefType "journal-article" @default.
• W4317686095 hasAuthorship W4317686095A5005677013 @default.
• W4317686095 hasAuthorship W4317686095A5013942253 @default.
• W4317686095 hasAuthorship W4317686095A5015256213 @default.
• W4317686095 hasAuthorship W4317686095A5015428877 @default.
• W4317686095 hasAuthorship W4317686095A5016669132 @default.
• W4317686095 hasAuthorship W4317686095A5016686763 @default.
• W4317686095 hasAuthorship W4317686095A5029588412 @default.
• W4317686095 hasAuthorship W4317686095A5042503296 @default.
• W4317686095 hasAuthorship W4317686095A5046981381 @default.
• W4317686095 hasAuthorship W4317686095A5049524331 @default.
• W4317686095 hasAuthorship W4317686095A5050435057 @default.
• W4317686095 hasAuthorship W4317686095A5051789976 @default.
• W4317686095 hasAuthorship W4317686095A5055537555 @default.
• W4317686095 hasAuthorship W4317686095A5060495866 @default.
• W4317686095 hasAuthorship W4317686095A5061348179 @default.
• W4317686095 hasAuthorship W4317686095A5066673450 @default.
• W4317686095 hasAuthorship W4317686095A5067211956 @default.
• W4317686095 hasAuthorship W4317686095A5068910261 @default.
• W4317686095 hasAuthorship W4317686095A5072284989 @default.
• W4317686095 hasAuthorship W4317686095A5072499869 @default.
• W4317686095 hasAuthorship W4317686095A5088007604 @default.
• W4317686095 hasBestOaLocation W43176860951 @default.
• W4317686095 hasConcept C121608353 @default.
• W4317686095 hasConcept C126322002 @default.
• W4317686095 hasConcept C143998085 @default.
• W4317686095 hasConcept C197934379 @default.
• W4317686095 hasConcept C2776256026 @default.
• W4317686095 hasConcept C2777701055 @default.
• W4317686095 hasConcept C2780057760 @default.
• W4317686095 hasConcept C2780580376 @default.
• W4317686095 hasConcept C71924100 @default.
• W4317686095 hasConcept C82210918 @default.
• W4317686095 hasConcept C90924648 @default.
• W4317686095 hasConceptScore W4317686095C121608353 @default.
• W4317686095 hasConceptScore W4317686095C126322002 @default.
• W4317686095 hasConceptScore W4317686095C143998085 @default.
• W4317686095 hasConceptScore W4317686095C197934379 @default.
• W4317686095 hasConceptScore W4317686095C2776256026 @default.
• W4317686095 hasConceptScore W4317686095C2777701055 @default.

• next